ID   MERTK_HUMAN             Reviewed;         999 AA.
AC   Q12866; Q9HBB4;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 2.
DT   02-NOV-2010, entry version 122.
DE   RecName: Full=Tyrosine-protein kinase Mer;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-Mer;
DE   AltName: Full=Receptor tyrosine kinase MerTK;
DE   Flags: Precursor;
GN   Name=MERTK; Synonyms=MER;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-118.
RC   TISSUE=Peripheral blood leukocyte;
RX   MEDLINE=94368701; PubMed=8086340;
RA   Graham D.K., Dawson T.L., Mullaney D.L., Snodgrass H.R., Earp H.S.;
RT   "Cloning and mRNA expression analysis of a novel human protooncogene,
RT   c-mer.";
RL   Cell Growth Differ. 5:647-657(1994).
RN   [2]
RP   ERRATUM.
RA   Graham D.K., Dawson T.L., Mullaney D.L., Snodgrass H.R., Earp H.S.;
RL   Cell Growth Differ. 5:1022-1022(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-999, VARIANTS RP LYS-540;
RP   CYS-661 AND THR-871, AND VARIANTS SER-20; ASN-118; THR-282; HIS-293;
RP   LYS-466; SER-498; VAL-518 AND VAL-871.
RX   MEDLINE=20517330; PubMed=11062461; DOI=10.1038/81555;
RA   Gal A., Li Y., Thompson D.A., Weir J., Orth U., Jacobson S.G.,
RA   Apfelstedt-Sylla E., Vollrath D.;
RT   "Mutations in MERTK, the human orthologue of the RCS rat retinal
RT   dystrophy gene, cause retinitis pigmentosa.";
RL   Nat. Genet. 26:270-271(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   INTERACTION WITH TNK2.
RX   PubMed=16288044; DOI=10.1158/0008-5472.CAN-05-1127;
RA   Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.;
RT   "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role
RT   of Ack1 in polyubiquitination of tumor suppressor Wwox.";
RL   Cancer Res. 65:10514-10523(2005).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-442, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [7]
RP   FUNCTION AS CELL ENTRY FACTOR IN FILOVIRUS INFECTION.
RX   PubMed=17005688; DOI=10.1128/JVI.01157-06;
RA   Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K.,
RA   Irimura T., Jones S., Feldmann H., Kawaoka Y.;
RT   "Tyro3 family-mediated cell entry of Ebola and Marburg viruses.";
RL   J. Virol. 80:10109-10116(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543; SER-613; TYR-929;
RP   SER-935; SER-968; SER-970 AND SER-979, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [9]
RP   STRUCTURE BY NMR OF 366-483.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the FN3 domain of human proto-oncogene
RT   tyrosine-protein kinase MER precursor.";
RL   Submitted (DEC-2006) to the PDB data bank.
RN   [10]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-20; ASN-118; MET-185; THR-282;
RP   LYS-289; HIS-293; GLY-446; LEU-452; LYS-466; SER-498; VAL-518;
RP   GLU-662; SER-708; GLN-823; TRP-865 AND ILE-870.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: In case of filovirus infection, seems to function as a
CC       cell entry factor.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts (upon activation) with TNK2; stimulates TNK2
CC       autophosphorylation.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein (By similarity).
CC   -!- TISSUE SPECIFICITY: Not expressed in normal B- and T-lymphocytes
CC       but is expressed in numerous neoplastic B- and T-cell lines.
CC   -!- DISEASE: Defects in MERTK are a cause of retinitis pigmentosa (RP)
CC       [MIM:268000]. RP that leads to degeneration of retinal
CC       photoreceptor cells. Patients typically have night vision
CC       blindness and loss of midperipheral visual field. As their
CC       condition progresses, they lose their far peripheral visual field
CC       and eventually central vision as well.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. AXL/UFO subfamily.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org//Genes/MERTKID41339ch2q13.html";
CC   -!- WEB RESOURCE: Name=Mutations of the MERTK gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.com/sci-news/mertkmut.htm";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U08023; AAB60430.1; -; mRNA.
DR   EMBL; AF260529; AAG33129.1; -; Genomic_DNA.
DR   EMBL; AF260514; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260515; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260516; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260517; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260518; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260519; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260520; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260521; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260522; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260523; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260524; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260525; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260526; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260527; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AF260528; AAG33129.1; JOINED; Genomic_DNA.
DR   EMBL; AC093675; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104651; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   IPI; IPI00029756; -.
DR   PIR; I38547; I38547.
DR   RefSeq; NP_006334.2; -.
DR   UniGene; Hs.306178; -.
DR   PDB; 2DBJ; NMR; -; A=373-483.
DR   PDB; 2P0C; X-ray; 2.40 A; A/B=570-864.
DR   PDB; 3BPR; X-ray; 2.80 A; A/B/C/D=574-864.
DR   PDB; 3BRB; X-ray; 1.90 A; A/B=570-864.
DR   PDBsum; 2DBJ; -.
DR   PDBsum; 2P0C; -.
DR   PDBsum; 3BPR; -.
DR   PDBsum; 3BRB; -.
DR   ProteinModelPortal; Q12866; -.
DR   SMR; Q12866; 101-280, 202-476, 280-479, 366-492.
DR   IntAct; Q12866; 2.
DR   STRING; Q12866; -.
DR   PhosphoSite; Q12866; -.
DR   PRIDE; Q12866; -.
DR   Ensembl; ENST00000295408; ENSP00000295408; ENSG00000153208.
DR   GeneID; 10461; -.
DR   KEGG; hsa:10461; -.
DR   NMPDR; fig|9606.3.peg.18483; -.
DR   UCSC; uc002thk.1; human.
DR   CTD; 10461; -.
DR   GeneCards; GC02P112656; -.
DR   H-InvDB; HIX0002374; -.
DR   HGNC; HGNC:7027; MERTK.
DR   MIM; 268000; phenotype.
DR   MIM; 604705; gene+phenotype.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA30759; -.
DR   HOGENOM; HBG444090; -.
DR   HOVERGEN; HBG006346; -.
DR   InParanoid; Q12866; -.
DR   OMA; TGPKHIP; -.
DR   OrthoDB; EOG905VM9; -.
DR   PhylomeDB; Q12866; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Reactome; REACT_604; Hemostasis.
DR   NextBio; 39667; -.
DR   ArrayExpress; Q12866; -.
DR   Bgee; Q12866; -.
DR   CleanEx; HS_MERTK; -.
DR   Genevestigator; Q12866; -.
DR   GermOnline; ENSG00000153208; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005625; C:soluble fraction; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kin...; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor linked signaling pathway; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   GO; GO:0050896; P:response to stimulus; IEA:UniProtKB-KW.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR020705; Tyr_prot_kinase_rcpt_MER.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 4.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF157; Tyr_prot_kinase_rcpt_MER; 1.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; FN_III-like; 2.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Receptor; Repeat; Retinitis pigmentosa; Sensory transduction; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Vision.
FT   SIGNAL        1     20       Potential.
FT   CHAIN        21    999       Tyrosine-protein kinase Mer.
FT                                /FTId=PRO_0000024443.
FT   TOPO_DOM     21    505       Extracellular (Potential).
FT   TRANSMEM    506    526       Helical; (Potential).
FT   TOPO_DOM    527    999       Cytoplasmic (Potential).
FT   DOMAIN       81    186       Ig-like C2-type 1.
FT   DOMAIN      197    273       Ig-like C2-type 2.
FT   DOMAIN      284    379       Fibronectin type-III 1.
FT   DOMAIN      383    482       Fibronectin type-III 2.
FT   DOMAIN      587    858       Protein kinase.
FT   NP_BIND     593    601       ATP (By similarity).
FT   ACT_SITE    723    723       Proton acceptor (By similarity).
FT   BINDING     615    615       ATP (By similarity).
FT   MOD_RES     543    543       Phosphoserine.
FT   MOD_RES     613    613       Phosphoserine.
FT   MOD_RES     754    754       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     929    929       Phosphotyrosine.
FT   MOD_RES     935    935       Phosphoserine.
FT   MOD_RES     968    968       Phosphoserine.
FT   MOD_RES     970    970       Phosphoserine.
FT   MOD_RES     979    979       Phosphoserine.
FT   CARBOHYD    114    114       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    170    170       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    207    207       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    215    215       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    294    294       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    316    316       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    329    329       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    336    336       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    354    354       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    389    389       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    395    395       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    442    442       N-linked (GlcNAc...).
FT   CARBOHYD    454    454       N-linked (GlcNAc...) (Potential).
FT   DISULFID    115    175       By similarity.
FT   DISULFID    218    262       By similarity.
FT   VARIANT      20     20       R -> S (in dbSNP:rs35898499).
FT                                /FTId=VAR_021039.
FT   VARIANT     118    118       S -> N (in dbSNP:rs13027171).
FT                                /FTId=VAR_021040.
FT   VARIANT     185    185       V -> M (in dbSNP:rs56205303).
FT                                /FTId=VAR_041741.
FT   VARIANT     282    282       A -> T (in dbSNP:rs7588635).
FT                                /FTId=VAR_021041.
FT   VARIANT     289    289       E -> K.
FT                                /FTId=VAR_041742.
FT   VARIANT     293    293       R -> H (in dbSNP:rs34072093).
FT                                /FTId=VAR_021042.
FT   VARIANT     329    329       N -> S (in dbSNP:rs34943572).
FT                                /FTId=VAR_051698.
FT   VARIANT     446    446       A -> G (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041743.
FT   VARIANT     452    452       V -> L (in dbSNP:rs34010621).
FT                                /FTId=VAR_041744.
FT   VARIANT     466    466       R -> K (in dbSNP:rs7604639).
FT                                /FTId=VAR_021043.
FT   VARIANT     498    498       N -> S (in dbSNP:rs35858762).
FT                                /FTId=VAR_021044.
FT   VARIANT     518    518       I -> V (in dbSNP:rs2230515).
FT                                /FTId=VAR_021045.
FT   VARIANT     540    540       E -> K (in RP).
FT                                /FTId=VAR_021046.
FT   VARIANT     661    661       S -> C (in RP).
FT                                /FTId=VAR_021047.
FT   VARIANT     662    662       Q -> E (in dbSNP:rs56209758).
FT                                /FTId=VAR_041745.
FT   VARIANT     708    708       A -> S (in a head & Neck squamous cell
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041746.
FT   VARIANT     823    823       E -> Q (in dbSNP:rs55924349).
FT                                /FTId=VAR_041747.
FT   VARIANT     865    865       R -> W (in dbSNP:rs2230516).
FT                                /FTId=VAR_020285.
FT   VARIANT     870    870       V -> I (in dbSNP:rs2230517).
FT                                /FTId=VAR_029237.
FT   VARIANT     871    871       I -> T (in RP).
FT                                /FTId=VAR_021048.
FT   VARIANT     871    871       I -> V.
FT                                /FTId=VAR_021049.
FT   CONFLICT    140    140       A -> G (in Ref. 1; AAB60430).
FT   CONFLICT    143    143       A -> R (in Ref. 1; AAB60430).
FT   CONFLICT    247    247       S -> G (in Ref. 1; AAB60430).
FT   CONFLICT    274    274       K -> Q (in Ref. 1; AAB60430).
FT   CONFLICT    328    328       S -> G (in Ref. 1; AAB60430).
FT   CONFLICT    628    628       Q -> H (in Ref. 1; AAB60430).
FT   CONFLICT    794    794       A -> R (in Ref. 1; AAB60430).
FT   CONFLICT    888    888       S -> P (in Ref. 1; AAB60430).
FT   TURN        577    580
FT   HELIX       584    586
FT   STRAND      587    594
FT   STRAND      601    607
FT   STRAND      613    620
FT   HELIX       635    642
FT   STRAND      654    656
FT   STRAND      668    672
FT   HELIX       679    685
FT   HELIX       697    716
FT   HELIX       726    728
FT   STRAND      729    731
FT   STRAND      737    739
FT   HELIX       764    766
FT   HELIX       769    773
FT   HELIX       779    794
FT   HELIX       806    808
FT   HELIX       809    814
FT   HELIX       827    835
FT   HELIX       841    843
FT   HELIX       847    859
SQ   SEQUENCE   999 AA;  110249 MW;  05BC339F05DFD355 CRC64;
     MGPAPLPLLL GLFLPALWRR AITEAREEAK PYPLFPGPFP GSLQTDHTPL LSLPHASGYQ
     PALMFSPTQP GRPHTGNVAI PQVTSVESKP LPPLAFKHTV GHIILSEHKG VKFNCSISVP
     NIYQDTTISW WKDGKELLGA HHAITQFYPD DEVTAIIASF SITSVQRSDN GSYICKMKIN
     NEEIVSDPIY IEVQGLPHFT KQPESMNVTR NTAFNLTCQA VGPPEPVNIF WVQNSSRVNE
     QPEKSPSVLT VPGLTEMAVF SCEAHNDKGL TVSKGVQINI KAIPSPPTEV SIRNSTAHSI
     LISWVPGFDG YSPFRNCSIQ VKEADPLSNG SVMIFNTSAL PHLYQIKQLQ ALANYSIGVS
     CMNEIGWSAV SPWILASTTE GAPSVAPLNV TVFLNESSDN VDIRWMKPPT KQQDGELVGY
     RISHVWQSAG ISKELLEEVG QNGSRARISV QVHNATCTVR IAAVTRGGVG PFSDPVKIFI
     PAHGWVDYAP SSTPAPGNAD PVLIIFGCFC GFILIGLILY ISLAIRKRVQ ETKFGNAFTE
     EDSELVVNYI AKKSFCRRAI ELTLHSLGVS EELQNKLEDV VIDRNLLILG KILGEGEFGS
     VMEGNLKQED GTSLKVAVKT MKLDNSSQRE IEEFLSEAAC MKDFSHPNVI RLLGVCIEMS
     SQGIPKPMVI LPFMKYGDLH TYLLYSRLET GPKHIPLQTL LKFMVDIALG MEYLSNRNFL
     HRDLAARNCM LRDDMTVCVA DFGLSKKIYS GDYYRQGRIA KMPVKWIAIE SLADRVYTSK
     SDVWAFGVTM WEIATRGMTP YPGVQNHEMY DYLLHGHRLK QPEDCLDELY EIMYSCWRTD
     PLDRPTFSVL RLQLEKLLES LPDVRNQADV IYVNTQLLES SEGLAQGSTL APLDLNIDPD
     SIIASCTPRA AISVVTAEVH DSKPHEGRYI LNGGSEEWED LTSAPSAAVT AEKNSVLPGE
     RLVRNGVSWS HSSMLPLGSS LPDELLFADD SSEGSEVLM
//
